Seeking Alpha

Cell Therapeutics regains rights to cancer compounds from Novartis

  • Cell Therapeutics (CTIC) will reacquire the rights to Pixuvri and Opaxio from Novartis (NVS) on the condition that NVS receive "certain potential payments ... based on sales [and] any sublicens[ing]."
  • "Regaining full rights to these two anti-cancer agents ... provides us with the flexibility to manage these assets within the context of our overall product portfolio strategy," CTIC CEO James Bianco says. (PR)
  • Recently: CTiC rallies on NICE nod for Pixuvri
  • CTIC +12% premarket
Comments (2)
  • Jibo
    , contributor
    Comments (105) | Send Message
    Based on just its present condition this stock should be between $7 and $9 today.
    21 Jan, 11:49 AM Reply Like
  • Jibo
    , contributor
    Comments (105) | Send Message
    Bears try to use an opportunity (slow down in Asia) today, they started shorting this stock at premarket for no particular reason. The question is why it is allowed to set sales price 10% less than the current market price on a premarket trade when there is no reason for it??? I guess we need new regulations on short sales as Europeans have already adopted more than a year ago.
    27 Jan, 10:03 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: